New hope for kids with relapsed brain cancer: experimental drug trial opens
NCT ID NCT07346157
Summary
This study is testing a drug called liothyronine (L-T3), both alone and combined with standard chemotherapy, for children and young adults whose medulloblastoma brain cancer has come back or gotten worse after initial treatment. The first part of the trial aims to find a safe dose, and the second part will see if the treatment can help control the cancer or clear tiny traces of it from the spinal fluid. It is for participants aged 1 to 25 years old.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.